Vantage Hemp is delighted to announce our partnership with Medcan Australia, to supply the company with pharmaceutical-grade CBD oils, distillates and isolates. The supply agreement symbolizes Vantage Hemp’s expansion into International CBD Markets and supports our mission to deliver premium quality cannabinoid extracts to the medical community worldwide. Australian cannabis sales approached $100 million in 2020, with 50,000 active patients. As the market gathers pace, aligning with Medcan empowers both companies to meet the demand for exceptional CBD oil extraction products, strengthening the global supply chain and reinforcing their respective leadership positions. With a license to import, cultivate, manufacture and export medicinal cannabis, Medcan was founded in 2016 with a commitment to provide Australians with high-quality and fairly priced products. Through vertical integration, the company has become a front runner in the regional market with Vantage Hemp ensuring superior quality, composition and reliability of its medical portfolio. The Australian market is poised for substantial growth in the near future, reaching $1.9 billion by 2026. The flourishing industry, combined with a buoyant economy, presents lucrative opportunities for the industry.